Vor Biopharma (NYSE:VOR) Major Shareholder Sells $656,000.00 in Stock

Key Points

• Reprogrammed Interchange LLC, the major shareholder of Vor Biopharma, recently sold a total of 400,000 shares for $656,000, bringing their ownership down to approximately 33.2 million shares.
• Vor Biopharma's stock price saw a decline, trading down 8.0% to $1.60, with a year-long trading range between a low of $0.13 and a high of $3.29.
• Analysts maintain a generally positive outlook, with five analysts rating the stock as a Buy and a consensus target price of $6.07.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 400,000 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $1.64, for a total value of $656,000.00. Following the transaction, the insider directly owned 33,228,487 shares in the company, valued at $54,494,718.68. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Friday, September 12th, Reprogrammed Interchange Llc sold 300,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.75, for a total value of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 284,805 shares of Vor Biopharma stock. The stock was sold at an average price of $1.83, for a total value of $521,193.15.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 464,421 shares of Vor Biopharma stock. The stock was sold at an average price of $1.99, for a total value of $924,197.79.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 350,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.82, for a total value of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 449,226 shares of Vor Biopharma stock. The stock was sold at an average price of $2.00, for a total value of $898,452.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.97, for a total value of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 453,016 shares of Vor Biopharma stock. The stock was sold at an average price of $1.93, for a total value of $874,320.88.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 554,612 shares of Vor Biopharma stock. The stock was sold at an average price of $2.00, for a total value of $1,109,224.00.
• On Thursday, August 28th, Reprogrammed Interchange Llc sold 806,351 shares of Vor Biopharma stock. The stock was sold at an average price of $2.01, for a total value of $1,620,765.51.
• On Wednesday, August 27th, Reprogrammed Interchange Llc sold 611,647 shares of Vor Biopharma stock. The stock was sold at an average price of $2.01, for a total value of $1,229,410.47.

Vor Biopharma Trading Down 8.0%

Vor Biopharma stock traded down $0.14 during trading on Monday, reaching $1.60. The company had a trading volume of 6,009,423 shares, compared to its average volume of 7,617,477. Vor Biopharma Inc. has a 52 week low of $0.13 and a 52 week high of $3.29. The firm has a market capitalization of $202.69 million, a price-to-earnings ratio of -0.97 and a beta of 2.05. The firm's 50-day simple moving average is $2.12 and its 200 day simple moving average is $1.13.

Analyst Upgrades and Downgrades

VOR has been the subject of a number of analyst reports. HC Wainwright reiterated a "buy" rating and issued a $3.00 price target on shares of Vor Biopharma in a research note on Thursday, August 14th. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $6.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new position in Vor Biopharma in the second quarter worth about $66,000. Goldman Sachs Group Inc. grew its position in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. Jane Street Group LLC purchased a new position in Vor Biopharma in the first quarter worth about $140,000. OMERS ADMINISTRATION Corp bought a new stake in Vor Biopharma in the first quarter worth about $100,000. Finally, Money Concepts Capital Corp lifted its stake in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.